FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2322460005> ?p ?o ?g. }

• W2322460005 endingPage "628" @default.
• W2322460005 startingPage "623" @default.
• W2322460005 abstract "The present phase II trial was performed to assess the efficacy and toxicity of polychemotherapy with gemcitabine and cisplatin in patients with locally advanced or metastatic carcinoma of the pancreas. Sixteen patients received six courses of an i.v. cytotoxic regimen consisting of gemcitabine (1000 mg/m2, days 1, 8 and 15) and cisplatin (35 mg/m2, days 1, 8 and 15) administered in 28-day intervals. Complete remission (CR) occurred in one patient (6%), partial remission (PR) in four patients (25%) and stable disease in seven patients (44%), whereas four patients (25%) developed progressive disease resulting in an overall response rate of 31%. Mean duration of responses (CR+PR) was 3.6 (range 0.7-8.5) months and mean time to progression was 7.4 (range 3.8-12.6) months. After a mean observation period of 11.5 months the overall survival was 9.6 months with 12 patients (75%) still being alive, which compares favorably with historical data of the administration of gemcitabine alone. The performance status improved in three (19%) and stabilized in eight (50%) out of 16 patients for 4 weeks or longer. Treatment-associated toxicity included alopecia of WHO grade III in all cases, leukopenia of WHO grades I and II in 10 patients (63%), grade III in five patients (31%), and thrombocytopenia grades I and II in four patients (25%), and grades III and IV in 10 patients (63%). We conclude that the administered dosage and schedule of gemcitabine and cisplatin in patients with locally advanced or metastatic cancer of the pancreas constitutes an active cytotoxic regimen associated with moderate toxicity." @default.
• W2322460005 created "2016-06-24" @default.
• W2322460005 creator A5011976466 @default.
• W2322460005 creator A5015139087 @default.
• W2322460005 creator A5038041875 @default.
• W2322460005 creator A5042560676 @default.
• W2322460005 creator A5047129352 @default.
• W2322460005 creator A5048694143 @default.
• W2322460005 creator A5049560644 @default.
• W2322460005 creator A5068091207 @default.
• W2322460005 creator A5068454507 @default.
• W2322460005 creator A5077961608 @default.
• W2322460005 date "2000-09-01" @default.
• W2322460005 modified "2023-09-26" @default.
• W2322460005 title "Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer" @default.
• W2322460005 cites W1890647543 @default.
• W2322460005 cites W1931508686 @default.
• W2322460005 cites W1981343121 @default.
• W2322460005 cites W2024210946 @default.
• W2322460005 cites W2036449594 @default.
• W2322460005 cites W2076649038 @default.
• W2322460005 cites W2084562398 @default.
• W2322460005 cites W2106642332 @default.
• W2322460005 cites W2135352785 @default.
• W2322460005 cites W2154737435 @default.
• W2322460005 cites W2285738680 @default.
• W2322460005 cites W2404671351 @default.
• W2322460005 cites W4237579923 @default.
• W2322460005 doi "https://doi.org/10.1097/00001813-200009000-00004" @default.
• W2322460005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11081453" @default.
• W2322460005 hasPublicationYear "2000" @default.
• W2322460005 type Work @default.
• W2322460005 sameAs 2322460005 @default.
• W2322460005 citedByCount "35" @default.
• W2322460005 countsByYear W23224600052012 @default.
• W2322460005 countsByYear W23224600052013 @default.
• W2322460005 countsByYear W23224600052016 @default.
• W2322460005 countsByYear W23224600052018 @default.
• W2322460005 countsByYear W23224600052021 @default.
• W2322460005 countsByYear W23224600052022 @default.
• W2322460005 countsByYear W23224600052023 @default.
• W2322460005 crossrefType "journal-article" @default.
• W2322460005 hasAuthorship W2322460005A5011976466 @default.
• W2322460005 hasAuthorship W2322460005A5015139087 @default.
• W2322460005 hasAuthorship W2322460005A5038041875 @default.
• W2322460005 hasAuthorship W2322460005A5042560676 @default.
• W2322460005 hasAuthorship W2322460005A5047129352 @default.
• W2322460005 hasAuthorship W2322460005A5048694143 @default.
• W2322460005 hasAuthorship W2322460005A5049560644 @default.
• W2322460005 hasAuthorship W2322460005A5068091207 @default.
• W2322460005 hasAuthorship W2322460005A5068454507 @default.
• W2322460005 hasAuthorship W2322460005A5077961608 @default.
• W2322460005 hasConcept C121608353 @default.
• W2322460005 hasConcept C126322002 @default.
• W2322460005 hasConcept C141071460 @default.
• W2322460005 hasConcept C2776694085 @default.
• W2322460005 hasConcept C2776907518 @default.
• W2322460005 hasConcept C2777844706 @default.
• W2322460005 hasConcept C2778239845 @default.
• W2322460005 hasConcept C2778822529 @default.
• W2322460005 hasConcept C2780210213 @default.
• W2322460005 hasConcept C2780258809 @default.
• W2322460005 hasConcept C2780873365 @default.
• W2322460005 hasConcept C2781413609 @default.
• W2322460005 hasConcept C29730261 @default.
• W2322460005 hasConcept C31760486 @default.
• W2322460005 hasConcept C71924100 @default.
• W2322460005 hasConcept C90924648 @default.
• W2322460005 hasConceptScore W2322460005C121608353 @default.
• W2322460005 hasConceptScore W2322460005C126322002 @default.
• W2322460005 hasConceptScore W2322460005C141071460 @default.
• W2322460005 hasConceptScore W2322460005C2776694085 @default.
• W2322460005 hasConceptScore W2322460005C2776907518 @default.
• W2322460005 hasConceptScore W2322460005C2777844706 @default.
• W2322460005 hasConceptScore W2322460005C2778239845 @default.
• W2322460005 hasConceptScore W2322460005C2778822529 @default.
• W2322460005 hasConceptScore W2322460005C2780210213 @default.
• W2322460005 hasConceptScore W2322460005C2780258809 @default.
• W2322460005 hasConceptScore W2322460005C2780873365 @default.
• W2322460005 hasConceptScore W2322460005C2781413609 @default.
• W2322460005 hasConceptScore W2322460005C29730261 @default.
• W2322460005 hasConceptScore W2322460005C31760486 @default.
• W2322460005 hasConceptScore W2322460005C71924100 @default.
• W2322460005 hasConceptScore W2322460005C90924648 @default.
• W2322460005 hasIssue "8" @default.
• W2322460005 hasLocation W23224600051 @default.
• W2322460005 hasLocation W23224600052 @default.
• W2322460005 hasOpenAccess W2322460005 @default.
• W2322460005 hasPrimaryLocation W23224600051 @default.
• W2322460005 hasRelatedWork W2090668979 @default.
• W2322460005 hasRelatedWork W2322460005 @default.
• W2322460005 hasRelatedWork W2356099210 @default.
• W2322460005 hasRelatedWork W2361287035 @default.
• W2322460005 hasRelatedWork W2369781240 @default.
• W2322460005 hasRelatedWork W2370615362 @default.
• W2322460005 hasRelatedWork W2371212030 @default.
• W2322460005 hasRelatedWork W2374795505 @default.
• W2322460005 hasRelatedWork W2601115157 @default.

• next